

Global Topoisomerase Inhibitors Market Growth 2024-2030

<https://marketpublishers.com/r/GCB77BBF3763EN.html>

Date: July 2024

Pages: 130

Price: US\$ 3,660.00 (Single User License)

ID: GCB77BBF3763EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Topoisomerase inhibitors are a new class of therapeutic drugs whose mechanism of action is to bind to the DNA-topoisomerase complex, causing DNA double-strand breaks and ultimately leading to cell apoptosis. As an ADC payload, topoisomerase is an alternative to the tubulin inhibitors widely used in ADCs in clinical trials.

The global Topoisomerase Inhibitors market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Topoisomerase Inhibitors Industry Forecast" looks at past sales and reviews total world Topoisomerase Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Topoisomerase Inhibitors sales for 2024 through 2030. With Topoisomerase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Topoisomerase Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Topoisomerase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Topoisomerase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Topoisomerase Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Topoisomerase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Topoisomerase Inhibitors.

United States market for Topoisomerase Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Topoisomerase Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Topoisomerase Inhibitors is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Topoisomerase Inhibitors players cover Roche, Mundipharma, Purdue Pharma, Debiopharm, Ipsen Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Topoisomerase Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Etoposide

Irinotecan

Topotecan

Other

Segmentation by Application:

Hospital

Clinic

Home Care

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Mundipharma

Purdue Pharma

Debiopharm

Ipsen Pharma

TopoGEN

Novartis

Hikma Pharmaceuticals

Viartis

Pfizer

Merrimack Pharmaceuticals

Amgen

Johnson & Johnson

BioMérieux

Promega

Takeda Pharmaceutical

Merck KGaA

Cipla

Teva Pharmaceuticals Industries

Key Questions Addressed in this Report

What is the 10-year outlook for the global Topoisomerase Inhibitors market?

What factors are driving Topoisomerase Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Topoisomerase Inhibitors market opportunities vary by end market size?

How does Topoisomerase Inhibitors break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Topoisomerase Inhibitors Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Topoisomerase Inhibitors by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Topoisomerase Inhibitors by Country/Region, 2019, 2023 & 2030
- 2.2 Topoisomerase Inhibitors Segment by Type
 - 2.2.1 Etoposide
 - 2.2.2 Irinotecan
 - 2.2.3 Topotecan
 - 2.2.4 Other
- 2.3 Topoisomerase Inhibitors Sales by Type
 - 2.3.1 Global Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Topoisomerase Inhibitors Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Topoisomerase Inhibitors Sale Price by Type (2019-2024)
- 2.4 Topoisomerase Inhibitors Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Home Care
- 2.5 Topoisomerase Inhibitors Sales by Application
 - 2.5.1 Global Topoisomerase Inhibitors Sale Market Share by Application (2019-2024)
 - 2.5.2 Global Topoisomerase Inhibitors Revenue and Market Share by Application (2019-2024)

2.5.3 Global Topoisomerase Inhibitors Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Topoisomerase Inhibitors Breakdown Data by Company

3.1.1 Global Topoisomerase Inhibitors Annual Sales by Company (2019-2024)

3.1.2 Global Topoisomerase Inhibitors Sales Market Share by Company (2019-2024)

3.2 Global Topoisomerase Inhibitors Annual Revenue by Company (2019-2024)

3.2.1 Global Topoisomerase Inhibitors Revenue by Company (2019-2024)

3.2.2 Global Topoisomerase Inhibitors Revenue Market Share by Company (2019-2024)

3.3 Global Topoisomerase Inhibitors Sale Price by Company

3.4 Key Manufacturers Topoisomerase Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Topoisomerase Inhibitors Product Location Distribution

3.4.2 Players Topoisomerase Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR TOPOISOMERASE INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Topoisomerase Inhibitors Market Size by Geographic Region (2019-2024)

4.1.1 Global Topoisomerase Inhibitors Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Topoisomerase Inhibitors Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Topoisomerase Inhibitors Market Size by Country/Region (2019-2024)

4.2.1 Global Topoisomerase Inhibitors Annual Sales by Country/Region (2019-2024)

4.2.2 Global Topoisomerase Inhibitors Annual Revenue by Country/Region (2019-2024)

4.3 Americas Topoisomerase Inhibitors Sales Growth

4.4 APAC Topoisomerase Inhibitors Sales Growth

4.5 Europe Topoisomerase Inhibitors Sales Growth

4.6 Middle East & Africa Topoisomerase Inhibitors Sales Growth

5 AMERICAS

5.1 Americas Topoisomerase Inhibitors Sales by Country

5.1.1 Americas Topoisomerase Inhibitors Sales by Country (2019-2024)

5.1.2 Americas Topoisomerase Inhibitors Revenue by Country (2019-2024)

5.2 Americas Topoisomerase Inhibitors Sales by Type (2019-2024)

5.3 Americas Topoisomerase Inhibitors Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Topoisomerase Inhibitors Sales by Region

6.1.1 APAC Topoisomerase Inhibitors Sales by Region (2019-2024)

6.1.2 APAC Topoisomerase Inhibitors Revenue by Region (2019-2024)

6.2 APAC Topoisomerase Inhibitors Sales by Type (2019-2024)

6.3 APAC Topoisomerase Inhibitors Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Topoisomerase Inhibitors by Country

7.1.1 Europe Topoisomerase Inhibitors Sales by Country (2019-2024)

7.1.2 Europe Topoisomerase Inhibitors Revenue by Country (2019-2024)

7.2 Europe Topoisomerase Inhibitors Sales by Type (2019-2024)

7.3 Europe Topoisomerase Inhibitors Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Topoisomerase Inhibitors by Country

8.1.1 Middle East & Africa Topoisomerase Inhibitors Sales by Country (2019-2024)

8.1.2 Middle East & Africa Topoisomerase Inhibitors Revenue by Country (2019-2024)

8.2 Middle East & Africa Topoisomerase Inhibitors Sales by Type (2019-2024)

8.3 Middle East & Africa Topoisomerase Inhibitors Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Topoisomerase Inhibitors

10.3 Manufacturing Process Analysis of Topoisomerase Inhibitors

10.4 Industry Chain Structure of Topoisomerase Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Topoisomerase Inhibitors Distributors

11.3 Topoisomerase Inhibitors Customer

12 WORLD FORECAST REVIEW FOR TOPOISOMERASE INHIBITORS BY GEOGRAPHIC REGION

- 12.1 Global Topoisomerase Inhibitors Market Size Forecast by Region
 - 12.1.1 Global Topoisomerase Inhibitors Forecast by Region (2025-2030)
 - 12.1.2 Global Topoisomerase Inhibitors Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Topoisomerase Inhibitors Forecast by Type (2025-2030)
- 12.7 Global Topoisomerase Inhibitors Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Roche

- 13.1.1 Roche Company Information
- 13.1.2 Roche Topoisomerase Inhibitors Product Portfolios and Specifications
- 13.1.3 Roche Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 Roche Main Business Overview
- 13.1.5 Roche Latest Developments

13.2 Mundipharma

- 13.2.1 Mundipharma Company Information
- 13.2.2 Mundipharma Topoisomerase Inhibitors Product Portfolios and Specifications
- 13.2.3 Mundipharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.2.4 Mundipharma Main Business Overview
- 13.2.5 Mundipharma Latest Developments

13.3 Purdue Pharma

- 13.3.1 Purdue Pharma Company Information
- 13.3.2 Purdue Pharma Topoisomerase Inhibitors Product Portfolios and Specifications
- 13.3.3 Purdue Pharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Purdue Pharma Main Business Overview
- 13.3.5 Purdue Pharma Latest Developments

13.4 Debiopharm

- 13.4.1 Debiopharm Company Information
- 13.4.2 Debiopharm Topoisomerase Inhibitors Product Portfolios and Specifications
- 13.4.3 Debiopharm Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.4.4 Debiopharm Main Business Overview

13.4.5 Debiopharm Latest Developments

13.5 Ipsen Pharma

13.5.1 Ipsen Pharma Company Information

13.5.2 Ipsen Pharma Topoisomerase Inhibitors Product Portfolios and Specifications

13.5.3 Ipsen Pharma Topoisomerase Inhibitors Sales, Revenue, Price and Gross

Margin (2019-2024)

13.5.4 Ipsen Pharma Main Business Overview

13.5.5 Ipsen Pharma Latest Developments

13.6 TopoGEN

13.6.1 TopoGEN Company Information

13.6.2 TopoGEN Topoisomerase Inhibitors Product Portfolios and Specifications

13.6.3 TopoGEN Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.6.4 TopoGEN Main Business Overview

13.6.5 TopoGEN Latest Developments

13.7 Novartis

13.7.1 Novartis Company Information

13.7.2 Novartis Topoisomerase Inhibitors Product Portfolios and Specifications

13.7.3 Novartis Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.7.4 Novartis Main Business Overview

13.7.5 Novartis Latest Developments

13.8 Hikma Pharmaceuticals

13.8.1 Hikma Pharmaceuticals Company Information

13.8.2 Hikma Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and

Specifications

13.8.3 Hikma Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue, Price and

Gross Margin (2019-2024)

13.8.4 Hikma Pharmaceuticals Main Business Overview

13.8.5 Hikma Pharmaceuticals Latest Developments

13.9 Viartis

13.9.1 Viartis Company Information

13.9.2 Viartis Topoisomerase Inhibitors Product Portfolios and Specifications

13.9.3 Viartis Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin

(2019-2024)

13.9.4 Viartis Main Business Overview

13.9.5 Viartis Latest Developments

13.10 Pfizer

13.10.1 Pfizer Company Information

13.10.2 Pfizer Topoisomerase Inhibitors Product Portfolios and Specifications

13.10.3 Pfizer Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Pfizer Main Business Overview

13.10.5 Pfizer Latest Developments

13.11 Merrimack Pharmaceuticals

13.11.1 Merrimack Pharmaceuticals Company Information

13.11.2 Merrimack Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and Specifications

13.11.3 Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Merrimack Pharmaceuticals Main Business Overview

13.11.5 Merrimack Pharmaceuticals Latest Developments

13.12 Amgen

13.12.1 Amgen Company Information

13.12.2 Amgen Topoisomerase Inhibitors Product Portfolios and Specifications

13.12.3 Amgen Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.12.4 Amgen Main Business Overview

13.12.5 Amgen Latest Developments

13.13 Johnson & Johnson

13.13.1 Johnson & Johnson Company Information

13.13.2 Johnson & Johnson Topoisomerase Inhibitors Product Portfolios and Specifications

13.13.3 Johnson & Johnson Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.13.4 Johnson & Johnson Main Business Overview

13.13.5 Johnson & Johnson Latest Developments

13.14 BioMérieux

13.14.1 BioMérieux Company Information

13.14.2 BioMérieux Topoisomerase Inhibitors Product Portfolios and Specifications

13.14.3 BioMérieux Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.14.4 BioMérieux Main Business Overview

13.14.5 BioMérieux Latest Developments

13.15 Promega

13.15.1 Promega Company Information

- 13.15.2 Promega Topoisomerase Inhibitors Product Portfolios and Specifications
- 13.15.3 Promega Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.15.4 Promega Main Business Overview
- 13.15.5 Promega Latest Developments
- 13.16 Takeda Pharmaceutical
 - 13.16.1 Takeda Pharmaceutical Company Information
 - 13.16.2 Takeda Pharmaceutical Topoisomerase Inhibitors Product Portfolios and Specifications
 - 13.16.3 Takeda Pharmaceutical Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.16.4 Takeda Pharmaceutical Main Business Overview
 - 13.16.5 Takeda Pharmaceutical Latest Developments
- 13.17 Merck KGaA
 - 13.17.1 Merck KGaA Company Information
 - 13.17.2 Merck KGaA Topoisomerase Inhibitors Product Portfolios and Specifications
 - 13.17.3 Merck KGaA Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.17.4 Merck KGaA Main Business Overview
 - 13.17.5 Merck KGaA Latest Developments
- 13.18 Cipla
 - 13.18.1 Cipla Company Information
 - 13.18.2 Cipla Topoisomerase Inhibitors Product Portfolios and Specifications
 - 13.18.3 Cipla Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.18.4 Cipla Main Business Overview
 - 13.18.5 Cipla Latest Developments
- 13.19 Teva Pharmaceuticals Industries
 - 13.19.1 Teva Pharmaceuticals Industries Company Information
 - 13.19.2 Teva Pharmaceuticals Industries Topoisomerase Inhibitors Product Portfolios and Specifications
 - 13.19.3 Teva Pharmaceuticals Industries Topoisomerase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.19.4 Teva Pharmaceuticals Industries Main Business Overview
 - 13.19.5 Teva Pharmaceuticals Industries Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Topoisomerase Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Topoisomerase Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Etoposide
- Table 4. Major Players of Irinotecan
- Table 5. Major Players of Topotecan
- Table 6. Major Players of Other
- Table 7. Global Topoisomerase Inhibitors Sales by Type (2019-2024) & (K Units)
- Table 8. Global Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)
- Table 9. Global Topoisomerase Inhibitors Revenue by Type (2019-2024) & (\$ million)
- Table 10. Global Topoisomerase Inhibitors Revenue Market Share by Type (2019-2024)
- Table 11. Global Topoisomerase Inhibitors Sale Price by Type (2019-2024) & (US\$/Unit)
- Table 12. Global Topoisomerase Inhibitors Sale by Application (2019-2024) & (K Units)
- Table 13. Global Topoisomerase Inhibitors Sale Market Share by Application (2019-2024)
- Table 14. Global Topoisomerase Inhibitors Revenue by Application (2019-2024) & (\$ million)
- Table 15. Global Topoisomerase Inhibitors Revenue Market Share by Application (2019-2024)
- Table 16. Global Topoisomerase Inhibitors Sale Price by Application (2019-2024) & (US\$/Unit)
- Table 17. Global Topoisomerase Inhibitors Sales by Company (2019-2024) & (K Units)
- Table 18. Global Topoisomerase Inhibitors Sales Market Share by Company (2019-2024)
- Table 19. Global Topoisomerase Inhibitors Revenue by Company (2019-2024) & (\$ millions)
- Table 20. Global Topoisomerase Inhibitors Revenue Market Share by Company (2019-2024)
- Table 21. Global Topoisomerase Inhibitors Sale Price by Company (2019-2024) & (US\$/Unit)
- Table 22. Key Manufacturers Topoisomerase Inhibitors Producing Area Distribution and Sales Area
- Table 23. Players Topoisomerase Inhibitors Products Offered

Table 24. Topoisomerase Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Topoisomerase Inhibitors Sales by Geographic Region (2019-2024) & (K Units)

Table 28. Global Topoisomerase Inhibitors Sales Market Share Geographic Region (2019-2024)

Table 29. Global Topoisomerase Inhibitors Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 30. Global Topoisomerase Inhibitors Revenue Market Share by Geographic Region (2019-2024)

Table 31. Global Topoisomerase Inhibitors Sales by Country/Region (2019-2024) & (K Units)

Table 32. Global Topoisomerase Inhibitors Sales Market Share by Country/Region (2019-2024)

Table 33. Global Topoisomerase Inhibitors Revenue by Country/Region (2019-2024) & (\$ millions)

Table 34. Global Topoisomerase Inhibitors Revenue Market Share by Country/Region (2019-2024)

Table 35. Americas Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 36. Americas Topoisomerase Inhibitors Sales Market Share by Country (2019-2024)

Table 37. Americas Topoisomerase Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 38. Americas Topoisomerase Inhibitors Sales by Type (2019-2024) & (K Units)

Table 39. Americas Topoisomerase Inhibitors Sales by Application (2019-2024) & (K Units)

Table 40. APAC Topoisomerase Inhibitors Sales by Region (2019-2024) & (K Units)

Table 41. APAC Topoisomerase Inhibitors Sales Market Share by Region (2019-2024)

Table 42. APAC Topoisomerase Inhibitors Revenue by Region (2019-2024) & (\$ millions)

Table 43. APAC Topoisomerase Inhibitors Sales by Type (2019-2024) & (K Units)

Table 44. APAC Topoisomerase Inhibitors Sales by Application (2019-2024) & (K Units)

Table 45. Europe Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 46. Europe Topoisomerase Inhibitors Revenue by Country (2019-2024) & (\$ millions)

Table 47. Europe Topoisomerase Inhibitors Sales by Type (2019-2024) & (K Units)

Table 48. Europe Topoisomerase Inhibitors Sales by Application (2019-2024) & (K

Units)

Table 49. Middle East & Africa Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)

Table 50. Middle East & Africa Topoisomerase Inhibitors Revenue Market Share by Country (2019-2024)

Table 51. Middle East & Africa Topoisomerase Inhibitors Sales by Type (2019-2024) & (K Units)

Table 52. Middle East & Africa Topoisomerase Inhibitors Sales by Application (2019-2024) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Topoisomerase Inhibitors

Table 54. Key Market Challenges & Risks of Topoisomerase Inhibitors

Table 55. Key Industry Trends of Topoisomerase Inhibitors

Table 56. Topoisomerase Inhibitors Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Topoisomerase Inhibitors Distributors List

Table 59. Topoisomerase Inhibitors Customer List

Table 60. Global Topoisomerase Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 61. Global Topoisomerase Inhibitors Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 62. Americas Topoisomerase Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 63. Americas Topoisomerase Inhibitors Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 64. APAC Topoisomerase Inhibitors Sales Forecast by Region (2025-2030) & (K Units)

Table 65. APAC Topoisomerase Inhibitors Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 66. Europe Topoisomerase Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 67. Europe Topoisomerase Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Middle East & Africa Topoisomerase Inhibitors Sales Forecast by Country (2025-2030) & (K Units)

Table 69. Middle East & Africa Topoisomerase Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 70. Global Topoisomerase Inhibitors Sales Forecast by Type (2025-2030) & (K Units)

Table 71. Global Topoisomerase Inhibitors Revenue Forecast by Type (2025-2030) & (\$

millions)

Table 72. Global Topoisomerase Inhibitors Sales Forecast by Application (2025-2030) & (K Units)

Table 73. Global Topoisomerase Inhibitors Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 74. Roche Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 75. Roche Topoisomerase Inhibitors Product Portfolios and Specifications

Table 76. Roche Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 77. Roche Main Business

Table 78. Roche Latest Developments

Table 79. Mundipharma Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 80. Mundipharma Topoisomerase Inhibitors Product Portfolios and Specifications

Table 81. Mundipharma Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 82. Mundipharma Main Business

Table 83. Mundipharma Latest Developments

Table 84. Purdue Pharma Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 85. Purdue Pharma Topoisomerase Inhibitors Product Portfolios and Specifications

Table 86. Purdue Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 87. Purdue Pharma Main Business

Table 88. Purdue Pharma Latest Developments

Table 89. Debiopharm Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 90. Debiopharm Topoisomerase Inhibitors Product Portfolios and Specifications

Table 91. Debiopharm Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 92. Debiopharm Main Business

Table 93. Debiopharm Latest Developments

Table 94. Ipsen Pharma Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 95. Ipsen Pharma Topoisomerase Inhibitors Product Portfolios and Specifications

Table 96. Ipsen Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

- Table 97. Ipsen Pharma Main Business
- Table 98. Ipsen Pharma Latest Developments
- Table 99. TopoGEN Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 100. TopoGEN Topoisomerase Inhibitors Product Portfolios and Specifications
- Table 101. TopoGEN Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 102. TopoGEN Main Business
- Table 103. TopoGEN Latest Developments
- Table 104. Novartis Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 105. Novartis Topoisomerase Inhibitors Product Portfolios and Specifications
- Table 106. Novartis Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 107. Novartis Main Business
- Table 108. Novartis Latest Developments
- Table 109. Hikma Pharmaceuticals Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 110. Hikma Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and Specifications
- Table 111. Hikma Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 112. Hikma Pharmaceuticals Main Business
- Table 113. Hikma Pharmaceuticals Latest Developments
- Table 114. Viatris Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 115. Viatris Topoisomerase Inhibitors Product Portfolios and Specifications
- Table 116. Viatris Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 117. Viatris Main Business
- Table 118. Viatris Latest Developments
- Table 119. Pfizer Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 120. Pfizer Topoisomerase Inhibitors Product Portfolios and Specifications
- Table 121. Pfizer Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 122. Pfizer Main Business
- Table 123. Pfizer Latest Developments
- Table 124. Merrimack Pharmaceuticals Basic Information, Topoisomerase Inhibitors

Manufacturing Base, Sales Area and Its Competitors

Table 125. Merrimack Pharmaceuticals Topoisomerase Inhibitors Product Portfolios and Specifications

Table 126. Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 127. Merrimack Pharmaceuticals Main Business

Table 128. Merrimack Pharmaceuticals Latest Developments

Table 129. Amgen Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 130. Amgen Topoisomerase Inhibitors Product Portfolios and Specifications

Table 131. Amgen Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 132. Amgen Main Business

Table 133. Amgen Latest Developments

Table 134. Johnson & Johnson Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 135. Johnson & Johnson Topoisomerase Inhibitors Product Portfolios and Specifications

Table 136. Johnson & Johnson Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 137. Johnson & Johnson Main Business

Table 138. Johnson & Johnson Latest Developments

Table 139. BioMérieux Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 140. BioMérieux Topoisomerase Inhibitors Product Portfolios and Specifications

Table 141. BioMérieux Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 142. BioMérieux Main Business

Table 143. BioMérieux Latest Developments

Table 144. Promega Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 145. Promega Topoisomerase Inhibitors Product Portfolios and Specifications

Table 146. Promega Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 147. Promega Main Business

Table 148. Promega Latest Developments

Table 149. Takeda Pharmaceutical Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 150. Takeda Pharmaceutical Topoisomerase Inhibitors Product Portfolios and

Specifications

Table 151. Takeda Pharmaceutical Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 152. Takeda Pharmaceutical Main Business

Table 153. Takeda Pharmaceutical Latest Developments

Table 154. Merck KGaA Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 155. Merck KGaA Topoisomerase Inhibitors Product Portfolios and Specifications

Table 156. Merck KGaA Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 157. Merck KGaA Main Business

Table 158. Merck KGaA Latest Developments

Table 159. Cipla Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 160. Cipla Topoisomerase Inhibitors Product Portfolios and Specifications

Table 161. Cipla Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 162. Cipla Main Business

Table 163. Cipla Latest Developments

Table 164. Teva Pharmaceuticals Industries Basic Information, Topoisomerase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 165. Teva Pharmaceuticals Industries Topoisomerase Inhibitors Product Portfolios and Specifications

Table 166. Teva Pharmaceuticals Industries Topoisomerase Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 167. Teva Pharmaceuticals Industries Main Business

Table 168. Teva Pharmaceuticals Industries Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Topoisomerase Inhibitors
- Figure 2. Topoisomerase Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Topoisomerase Inhibitors Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Topoisomerase Inhibitors Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Topoisomerase Inhibitors Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Topoisomerase Inhibitors Sales Market Share by Country/Region (2023)
- Figure 10. Topoisomerase Inhibitors Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of Etoposide
- Figure 12. Product Picture of Irinotecan
- Figure 13. Product Picture of Topotecan
- Figure 14. Product Picture of Other
- Figure 15. Global Topoisomerase Inhibitors Sales Market Share by Type in 2023
- Figure 16. Global Topoisomerase Inhibitors Revenue Market Share by Type (2019-2024)
- Figure 17. Topoisomerase Inhibitors Consumed in Hospital
- Figure 18. Global Topoisomerase Inhibitors Market: Hospital (2019-2024) & (K Units)
- Figure 19. Topoisomerase Inhibitors Consumed in Clinic
- Figure 20. Global Topoisomerase Inhibitors Market: Clinic (2019-2024) & (K Units)
- Figure 21. Topoisomerase Inhibitors Consumed in Home Care
- Figure 22. Global Topoisomerase Inhibitors Market: Home Care (2019-2024) & (K Units)
- Figure 23. Global Topoisomerase Inhibitors Sale Market Share by Application (2023)
- Figure 24. Global Topoisomerase Inhibitors Revenue Market Share by Application in 2023
- Figure 25. Topoisomerase Inhibitors Sales by Company in 2023 (K Units)
- Figure 26. Global Topoisomerase Inhibitors Sales Market Share by Company in 2023
- Figure 27. Topoisomerase Inhibitors Revenue by Company in 2023 (\$ millions)
- Figure 28. Global Topoisomerase Inhibitors Revenue Market Share by Company in 2023
- Figure 29. Global Topoisomerase Inhibitors Sales Market Share by Geographic Region

(2019-2024)

Figure 30. Global Topoisomerase Inhibitors Revenue Market Share by Geographic Region in 2023

Figure 31. Americas Topoisomerase Inhibitors Sales 2019-2024 (K Units)

Figure 32. Americas Topoisomerase Inhibitors Revenue 2019-2024 (\$ millions)

Figure 33. APAC Topoisomerase Inhibitors Sales 2019-2024 (K Units)

Figure 34. APAC Topoisomerase Inhibitors Revenue 2019-2024 (\$ millions)

Figure 35. Europe Topoisomerase Inhibitors Sales 2019-2024 (K Units)

Figure 36. Europe Topoisomerase Inhibitors Revenue 2019-2024 (\$ millions)

Figure 37. Middle East & Africa Topoisomerase Inhibitors Sales 2019-2024 (K Units)

Figure 38. Middle East & Africa Topoisomerase Inhibitors Revenue 2019-2024 (\$ millions)

Figure 39. Americas Topoisomerase Inhibitors Sales Market Share by Country in 2023

Figure 40. Americas Topoisomerase Inhibitors Revenue Market Share by Country (2019-2024)

Figure 41. Americas Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)

Figure 42. Americas Topoisomerase Inhibitors Sales Market Share by Application (2019-2024)

Figure 43. United States Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 44. Canada Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 45. Mexico Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 46. Brazil Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 47. APAC Topoisomerase Inhibitors Sales Market Share by Region in 2023

Figure 48. APAC Topoisomerase Inhibitors Revenue Market Share by Region (2019-2024)

Figure 49. APAC Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)

Figure 50. APAC Topoisomerase Inhibitors Sales Market Share by Application (2019-2024)

Figure 51. China Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 52. Japan Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 53. South Korea Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 54. Southeast Asia Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 55. India Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 56. Australia Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 57. China Taiwan Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$

millions)

Figure 58. Europe Topoisomerase Inhibitors Sales Market Share by Country in 2023

Figure 59. Europe Topoisomerase Inhibitors Revenue Market Share by Country (2019-2024)

Figure 60. Europe Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)

Figure 61. Europe Topoisomerase Inhibitors Sales Market Share by Application (2019-2024)

Figure 62. Germany Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 63. France Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 64. UK Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 65. Italy Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 66. Russia Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 67. Middle East & Africa Topoisomerase Inhibitors Sales Market Share by Country (2019-2024)

Figure 68. Middle East & Africa Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)

Figure 69. Middle East & Africa Topoisomerase Inhibitors Sales Market Share by Application (2019-2024)

Figure 70. Egypt Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 71. South Africa Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 72. Israel Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 73. Turkey Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 74. GCC Countries Topoisomerase Inhibitors Revenue Growth 2019-2024 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Topoisomerase Inhibitors in 2023

Figure 76. Manufacturing Process Analysis of Topoisomerase Inhibitors

Figure 77. Industry Chain Structure of Topoisomerase Inhibitors

Figure 78. Channels of Distribution

Figure 79. Global Topoisomerase Inhibitors Sales Market Forecast by Region (2025-2030)

Figure 80. Global Topoisomerase Inhibitors Revenue Market Share Forecast by Region (2025-2030)

Figure 81. Global Topoisomerase Inhibitors Sales Market Share Forecast by Type (2025-2030)

Figure 82. Global Topoisomerase Inhibitors Revenue Market Share Forecast by Type (2025-2030)

Figure 83. Global Topoisomerase Inhibitors Sales Market Share Forecast by Application (2025-2030)

Figure 84. Global Topoisomerase Inhibitors Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Topoisomerase Inhibitors Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GCB77BBF3763EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCB77BBF3763EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970